News | April 21, 2010

Drug-Eluting Stents Help Patients Avoid Amputation

The Xience is among several drug-eluting coronary stents used off-label in a study to improve high restenosis rates lesions below the knee.

April 21, 2010 – More than 100,000 amputations are performed each year in the United States on patients with critical limb ischemia (CLI), the most severe form of peripheral arterial disease (PAD). Interventional radiologists have found a subgroup of patients with CLI may avoid amputation through the use of drug-eluting stents on the smaller arteries below the knee, according to a recent single-center study.

"Drug-eluting stents are an emerging technology that offers hope to PAD patients with critical limb ischemia and freedom from major amputations,” said Robert A. Lookstein, M.D., an interventional radiologist and associate director of the division of interventional radiology at Mount Sinai Medical Center in New York. “The placement of drug-eluting stents in the infrapopliteal leg arteries is safe and effective and can significantly impact their care. Our results rival bypass surgery and are better than balloon angioplasty alone."

Primary patency (length of time the blood vessels stayed open and moved blood flow efficiently) for the 53-patient study at 12 months was 81.8 percent, said Dr. Lookstein, who also is an associate professor of radiology and surgery at Mount Sinai School of Medicine. Freedom from major amputation at follow-up was 90.6 percent for the entire group and 100 percent for patients with Rutherford category 4 (ischemic pain at rest) and 5 (lower-extremity ischemia associated with minor tissue loss) disease. The Rutherford categories are a severity classification scale for PAD that can be used to evaluate clinical improvement. Patients were followed for an average of 17 months.

Surgical bypass remains the mainstream therapy for blocked infrapopliteal arteries, but there are a growing number of patients who are unable to undergo this treatment because of their medical problems, said Dr. Lookstein. Attempts to treat CLI in PAD patients with below-the-knee angioplasty are hindered by high rates of restenosis, the need for repeat treatments and the continued progression of atherosclerotic disease. Drug-eluting stents are a potential solution to the limitations of endovascular treatment.

Over a four-year period, Dr. Lookstein's group at Mount Sinai Medical Center in New York studied 53 patients (32 men, 21 women) ranging in age from 43 to 93 who underwent implantation of 94 drug-eluting stents (80 sirolimus, 12 everolimus, 2 paclitaxel) to treat a suboptimal angioplasty result in an infrapopliteal artery. All patients had symptoms of critical limb ischemia with Rutherford grade 4, 5 or 6 disease at presentation prior to treatment. Initial technical success rate was 100 percent with all treated lesions having less than 10 percent residual angiographic stenosis at completion of the procedure. The mean number of stents placed per patient was 1.62 (range, 1-5), with the stent diameter ranging from 2.5 to 4 millimeters.

Angiographic, clinical and noninvasive vascular examination results were collected prospectively at regular intervals. Primary endpoints, including technical success of the revascularization procedure, primary patency, freedom from major amputation and survival at follow-up, rival those of conventional bypass surgery.

"Our study reinforces the fact that when it comes to treating cardiovascular disease, there is a wide range of safe and effective treatments," said Dr. Lookstein.

Multicenter randomized trials are necessary to support such promising results of the value of infrapopliteal drug-eluting stents in critical limb ischemia treatments, he added. In the United States, drug-eluting stents are FDA-approved for the coronary arteries but not for infrapopliteal arteries.

For more information: www.SIRweb.org

Reference:

"Single Center Experience With Drug-eluting Stents for Infrapopliteal Occlusive Disease in Patients With Critical Limb Ischemia," A.M. Fischman, S.S. Shah, E. Kim, P. Stangl, F. Nowakowski, J.L. Weintraub, R. Lookstein, all at Mount Sinai Medical Center, New York, N.Y., Society of Interventional Radiology 35th Annual Scientific Meeting March 13-18, 2010, Tampa, Fla.

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init